Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
Explore this paper's citation graph
Summary
Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
- Type
- article
- Published
- 1998-09-16
- Cited by
- 2,681
- References
- 26
- OpenAlex
- https://openalex.org/W2117792530
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:73394411
Keywords
Medicine, Prostate cancer, Androgen deprivation therapy, Prostatectomy, Urology
References
- Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
- Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer.
- Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial.
- Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.
- A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma
- Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation.
- Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.
- Salvage radical prostatectomy for adenocarcinoma of the prostate
- Histologic Grading and Staging of Prostatic Carcinoma
- Outcome based staging for clinically localized adenocarcinoma of the prostate.
- Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
- Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome.
- Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
- Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
- Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma.
- Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
- Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.
- Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma.
- Consensus statement: Guidelines for PSA following radiation therapy
- Results of conservative management of clinically localized prostate cancer.
Cited by
- Operative Therapie des lokal begrenzten Prostatakarzinoms
- Permanent radioactive seed implantation in the treatment of prostate cancer.
- Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer?
- Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer.
- Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
- Frozen section diagnosis of metastatic prostate adenocarcinoma in pelvic lymphadenectomy compared with nomogram prediction of metastasis.
- Biochemical Outcome for Hormone‐Naïve Patients with High‐Risk Prostate Cancer Managed with Permanent Interstitial Br achy therapy and Supplemental External‐Beam Radiation
- Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma.
- Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer.
- Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
- Internal audit of a comprehensive IMRT program for prostate cancer: a model for centers in developing countries?
- Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study
- HDR monotherapy for man with radiotherapy contraindications and prostate cancer.
- Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer
- Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy
- Radiotherapy of prostate cancer.
- Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy.
- Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis.
- Quality indicators for prostate radiotherapy: Are patients disadvantaged by receiving treatment in a ‘generalist’ centre?
- Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer
Related papers
- Prostate specific antigen nadir determined using ultra‐sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males
- Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
- ULTRASENSITIVE DETECTION OF PROSTATE SPECIFIC ANTIGEN IN THE FOLLOWUP OF 422 PATIENTS AFTER RADICAL PROSTATECTOMY
- Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
- Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy.
- Re: Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.
- Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.
- Простатспецифический антиген – предиктор эффективности спасительной лучевой терапии больных с рецидивами рака предстательной железы после радикальной простатэктомии
- Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.